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Abstract
Background: Organizations have been established in many countries and internationally to support the use of research
evidence by producing clinical practice guidelines, undertaking health technology assessments, and/or directly supporting
the use of research evidence in developing health policy on an international, national, and state or provincial level.
Learning from these organizations can reduce the need to 'reinvent the wheel' and inform decisions about how best to
organize support for such organizations, particularly in low- and middle-income countries (LMICs).
Methods: We undertook a multi-method study in three phases – a survey, interviews, and case descriptions that drew
on site visits – and in each of the second and third phases we focused on a purposive sample of those involved in the
previous phase. We used the seven main recommendations that emerged from the advice offered in the interviews to
organize much of the synthesis of findings across phases and methods. We used a constant comparative method to
identify themes from across phases and methods.
Results: Seven recommendations emerged for those involved in establishing or leading organizations that support the
use of research evidence in developing health policy: 1) collaborate with other organizations; 2) establish strong links
with policymakers and involve stakeholders in the work; 3) be independent and manage conflicts of interest among those
involved in the work; 4) build capacity among those working in the organization; 5) use good methods and be transparent
in the work; 6) start small, have a clear audience and scope, and address important questions; and 7) be attentive to
implementation considerations, even if implementation is not a remit. Four recommendations emerged for the World
Health Organization (WHO) and other international organizations and networks: 1) support collaborations among
organizations; 2) support local adaptation efforts; 3) mobilize support; and 4) create global public goods.
Conclusion: This synthesis of findings from a multi-method study, along with the more detailed findings from each of
the three phases of the study (which are reported in the three following articles in the series), provide a strong basis on
which researchers, policymakers, international organizations (and networks) like WHO can respond to the growing
chorus of voices calling for efforts to support the use of research evidence in developing health policy.
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Background
Over the past three years, there has been a great deal of
international discussion about how to harness health
research evidence more effectively in order to achieve the
United Nations' millennium development goals as well as
national health goals, particularly in low- and middle-
income countries (LMICs). One important focus in this
discussion has been the call to develop mechanisms to
support the use of research evidence in developing clinical
practice guidelines, health technology assessments, and
health policy. The chapter on linking research to action in
the World Report on Knowledge for Better Health that was
released by the World Health Organization (WHO) in
early November 2004 provided a framework for appreci-
ating the diversity and complementarities of many of
these mechanisms [1]. The health ministers and heads of
national delegations from 58 countries who participated
in the Ministerial Summit on Health Research that was
held in Mexico City in November 2004 reiterated the call
for developing such support mechanisms [2].
At the World Health Assembly that was held in Geneva in
May 2005, these debates culminated in the passage of a
two-part resolution that established specific accountabili-
ties for developing mechanisms to support the use of
research evidence in developing health policy [3]. The first
part of the resolution called on WHO member states to
'establish or strengthen mechanisms to transfer knowl-
edge in support of evidence-based public health and
health-care delivery systems, and evidence-based health-
related policies.' The second part of the resolution called
on WHO's Director-General to 'assist in the development
of more effective mechanisms to bridge the divide
between ways in which knowledge is generated and ways
in which it is used, including the transformation of
health-research findings into policy and practice.'
Organizations have already been established in many
countries and internationally to support the use of
research evidence in developing health policy. These
include organizations that produce clinical practice guide-
lines (CPG), undertake health technology assessment
(HTA), and directly support the use of research evidence
in developing health policy on an international, national,
and state or provincial level (hereafter called government
support units, or GSUs). While there may be important
differences among these organizations, there may also be
many commonalities and opportunities for existing and
new organizations to learn from this collective experience.
A review of this experience can reduce the need to 'rein-
vent the wheel' and inform decisions about how best to
organize support for evidence-informed health policy
development processes.
An important dimension of the context for any such
review is the growing demand for more rigorous processes
to ensure that decision-making is well informed by the
best available research evidence. These processes, in con-
trast with traditional approaches that rely heavily on the
opinions of experts, demand systematic and transparent
approaches to access, synthesise, and interpret research
evidence and to integrate that evidence with other infor-
mation, values, and judgements in order to formulate rec-
ommendations or make decisions. The need for more
rigorous processes to support clinical decision-making is
underscored by evidence of inconsistencies between the
available research evidence and expert recommendations
[4,5], insufficient use of the available research evidence
[6,7], and other shortcomings in how guidelines and rec-
ommendations are developed [8-15]. Similar criticisms
have been voiced and calls made for the better use of
research evidence in health systems management and
public policy-making [1-3,16-18].
Our objective was to identify organizations around the
world, and especially in LMICs, that are in some way suc-
cessful or innovative in supporting the use of research evi-
dence in the development of CPGs, HTAs, and health
policy, and to describe their experiences. We pursued this
objective in a three-phase, multi-method study [19]. In
this article, we provide a synthesis of findings from across
phases and methods. In the following three articles in the
series, we provide more detail about the methods and
findings from each of the three phases (Table 1).
Methods
In order to support our primary focus on LMICs, we con-
vened a project reference group that drew on two or three
individuals who were from, or who are very knowledgea-
ble about, Africa, Asia, or Latin America, as well as indi-
viduals from North America, Europe (including a
representative from the project funder), and WHO
(including members of the Advisory Committee on
Health Research). Collectively, the reference group pro-
vided many perspectives on the three types of organiza-
tions under study and on potential country- or region-
level differences in the opportunities and challenges con-
fronting these organizations. The reference group pro-
vided feedback on our draft protocol, study population,
questionnaire, interview guide, and case study data collec-
tion plan. We also engaged one individual from each of
Africa, Asia, Europe, and Latin America to provide a very
detailed review of the draft final report on which this
series of articles is based.
We undertook the project in three phases – a survey, inter-
views, and case descriptions that drew on site visits – and
in each of the second and third phases we focused on a
purposive sample of those involved in the previous phase.
We drew on many people and organizations around the
world to generate a list of organizations to survey. We
modified a questionnaire that had been developed origi-Implementation Science 2008, 3:53 http://www.implementationscience.com/content/3/1/53
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nally by the Appraisal of Guidelines, Research and Evalu-
ation in Europe (AGREE) collaboration, adapted one
version of the questionnaire for organizations producing
CPGs and HTAs and another for GSUs, piloted both ver-
sions of the questionnaire, and made a small number of
final modifications to both versions of the questionnaire
[20]. We sent the questionnaire by email to 176 organiza-
tions and followed up periodically with non-responders
by email and telephone. We then purposively sampled 25
organizations from among those who responded to the
survey. We developed and piloted an interview guide and
used the guide to conduct interviews by telephone with
the director of each organization [21]. We then purpo-
sively sampled eight cases of one or more organizations
supporting the use of research evidence from among the
cases described in the interviews and (once) from among
other cases with which we were familiar. We developed
and piloted a case study data collection plan and con-
ducted site visits for each case [22]. Data collection for the
case studies included interviews with 51 key informants
and a review of publicly available documents. We con-
ducted simple descriptive statistics using the quantitative
survey data and we analysed the written survey responses,
interviews, in-person interviews, and documents using a
constant comparative method of analysis. We produced a
video documentary about each case.
We used the seven main recommendations that emerged
from the advice offered in the interviews to organize much
of the synthesis of findings across phases and methods.
We chose this organizing framework for three reasons: 1)
our interest is in the views and experiences of particularly
successful or innovative groups (particularly those based
in LMICs), and the interviews allowed us to balance
breadth and depth in soliciting these views and experi-
ences; 2) the thematic analysis of the interview data
yielded clear recommendations for other organizations;
and 3) the analysis of the quantitative survey data, the
written survey responses (which we call the qualitative
survey data), and the case descriptions reinforced the
broad applicability of the organizing framework. We used
a constant comparative method to identify from across
phases and methods themes relevant to WHO and other
international organizations and networks.
The principal investigator for the overall project (AO),
who is based in Norway, confirmed that, in accordance
with the country's act on ethics and integrity in research,
this study did not require ethics approval from one of the
country's four Regional Committees for Medical and
Health Research Ethics.
Results
Seven recommendations emerged from the multi-method
study for those involved in establishing or leading organ-
izations that support the use of research evidence in devel-
oping health policy:
Collaborate with other organizations
This advice was reinforced by: 1) the (quantitative) survey
finding that more than half of the organizations (and par-
ticularly HTA agencies) reported that examples from other
countries were helpful in establishing their organization;
2) the (qualitative) survey finding that many organiza-
tions producing CPGs or HTAs conducted a focused
review of one particular organization that they then emu-
lated or a broad review of a variety of organizational mod-
els; 3) the (qualitative) survey finding that the advice that
was most commonly offered by organizations producing
CPGs, HTAs, or both was to seek support from similar
existing organizations or networks, whether through
informal interactions, study tours, mentoring relation-
ships, twinning, partnerships or network memberships;
4) the (qualitative) survey finding that working within
national networks and, more generally, collaborating
rather than competing with other bodies, was a com-
monly cited strength in how GSUs are organized; and 5)
the case descriptions finding that one of the two types of
advice offered to other organizations was to learn from
other organizations.
Establish strong links with policymakers and involve 
stakeholders in the work
This advice was reinforced by: 1) the (quantitative) survey
finding that a high proportion (88%) of GSUs involved
Table 1: Overview of the four-article series
This article Synthesis of findings from the three-phase, multi-method study
[20] Survey of a senior staff member (the director or his or her nominee) of clinical practice guideline-producing organizations, 
HTA agencies, and government support units
[21] Interview with the senior staff member of a purposively sampled sub-group of these three types of organizations, with an 
emphasis on those organizations that were particularly successful or innovative
[22] Case descriptions (based on site visits) of one or more organizations supporting the use of research evidence from among 
the cases described in the interviews and (once) other cases with which we were familiar, again with an emphasis on those 
organizations that were particularly successful or innovativeImplementation Science 2008, 3:53 http://www.implementationscience.com/content/3/1/53
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target users in the selection of topics or the services under-
taken; 2) the interview finding that, while informal rela-
tionships with policymakers were identified more
frequently as important by GSUs than by organizations
producing CPGs, HTAs, or both, nearly all of the organi-
zations reported using personal communications with
decision-makers, and particularly with policymakers; 3)
the interview finding that organizations both within and
outside government viewed their close links with policy-
makers as a strength; and 4) the case descriptions finding
that the existence of a strong relationship between
researchers and policymakers was repeatedly cited as one
of two key organizational strengths (although this
strength brought with it a related challenge, namely the
need to manage the conflicts of interest that can emerge in
any close relationship between researchers and policy-
makers).
Be independent and manage conflicts of interest among 
those involved in the work
This advice was reinforced by: 1) the (qualitative) survey
finding that independence is by far the most commonly
cited strength in how organizations producing CPGs and
HTAs are organized; and 2) the case descriptions finding
that the presence of conflicts of interest was repeatedly
cited as one of two key organizational weaknesses.
Build capacity among those working in the organization
This advice was reinforced by: 1) the (quantitative) survey
finding that most organizations have a small number of
full-time equivalent (FTE) staff; 2) and the case descrip-
tions finding that developing capacity among and retain-
ing skilled staff and collaborators was one of their two
frequently offered types of advice.
Use good methods and be transparent in the work
This advice was reinforced by: 1) the (quantitative) survey
finding that between 84% and 100% of organizations
reported providing panels with or using systematic
reviews; 2) the (qualitative) survey finding that an evi-
dence-based approach is the most commonly cited
strength of the methods used by organizations that pro-
duce CPGs and HTAs; 3) the interview finding that using
rigorous methods that are systematic and transparent
(sometimes shortened to 'being evidence-based') was the
most commonly cited strength among all organizations;
and 4) the case descriptions finding that the use of an evi-
dence-based approach was one of two organizational
strengths that were repeatedly cited. However, all but one
of the organizations producing CPGs, HTAs, or both used
informal methods for setting priorities. Relatively few
organizations producing CPGs and HTAs convened
groups to develop CPGs or HTAs, took equity considera-
tions into account, or had established a process for
addressing conflicts of interest. GSUs were less likely to
have a manual that described the methods they use and to
conduct or use systematic reviews and more likely to
report using non-systematic methods to review the litera-
ture. In addition, using systematic and transparent meth-
ods brought with it a related challenge, namely the time-
consuming nature of an evidence-based approach.
Start small, have a clear audience and scope, and address 
important questions
This finding was reinforced by: 1) the (qualitative) survey
finding that the most commonly cited weakness in how
these organizations are organized is a lack of resources,
both financial and human; 2) the (qualitative) survey
finding that the most commonly cited weakness of the
methods used by organizations that produce CPGs and
HTAs was their time-consuming and labour-intensive
nature; 3) the (qualitative) survey finding that GSUs
advised others establishing a similar organization to
attend to the need for secure funding; 4) the interview
finding that the weakness noted by most of the CPG- and
HTA-producing organizations was inadequate resources,
more specifically insufficient numbers of skilled staff and
time, together with using labour- and time-intensive proc-
esses that limit the number and quality of CPGs and HTAs
that can be produced and updated; and 5) the case
descriptions finding that a lack of resources was repeat-
edly cited as one of two organizational weaknesses.
Be attentive to implementation considerations even if 
implementation is not a remit
This advice was reinforced by: 1) the (quantitative) survey
finding that less than half of all organizations provided a
summary of take-home messages in their products; 2) the
(quantitative) survey finding that between one-half and
two-thirds of organizations do not collect data systemati-
cally about uptake; 3) the (qualitative) survey finding that
the most commonly cited weaknesses of CPG- and HTA-
producing organizations' outputs are the lack of dissemi-
nation and implementation strategies for the outputs, and
the lack of monitoring and evaluation of impact; 4) the
interview finding that most organizations argued that it is
the clients who requested a CPG or HTA – typically, the
minister of health or more generally the department of
health – who is responsible for implementing recommen-
dations or policy decisions; 5) the interview finding that
all types of organizations tended to focus largely on weak-
nesses in implementation when asked about both
strengths and weaknesses, with few exceptions; and 6) the
interview finding that most of the examples of success
among organizations producing CPGs, HTAs, or both
were occasions where there was a perception that clini-
cians adhered to the organization's recommendations or
policymakers based their decisions (at least in part) on the
work of the organization.Implementation Science 2008, 3:53 http://www.implementationscience.com/content/3/1/53
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Four recommendations emerged from the multi-method
study for WHO, most of which were equally relevant for
other international organizations and for networks such
as the Guidelines International Network and the Interna-
tional Network of Agencies for Health Technology Assess-
ment. The first recommendation was to support
collaborations among organizations. This advice is sup-
ported by: 1) the (qualitative) survey finding that many
CPG- and HTA-producing organizations argued that
WHO should play a facilitating role in coordination
efforts, primarily to avoid duplication; and 2) the inter-
view finding that when comments about WHO's potential
role were offered they almost always pertained to the need
to foster collaborations across organizations. The second
recommendation was to support local adaptation efforts.
This advice is supported by: 1) the (qualitative) survey
finding that some CPG- and HTA-producing organiza-
tions argued that WHO should play a facilitating role in
local adaptation efforts in order to enhance local applica-
bility; and 2) the (qualitative) survey finding that some
GSUs argued that WHO should play a role in helping to
adapt global evidence to local contexts or at least in sup-
porting such processes. The third recommendation was to
mobilize support. This advice is supported by the case
descriptions finding that one of only two suggestions that
were offered with any frequency was that WHO should
play a role in mobilizing one or more of government sup-
port, financial resources, and the participation of both
policymakers and researchers. And the fourth recommen-
dation was to create global public goods, which was sup-
ported by the case description finding that the second of
only two suggestions that were offered with any frequency
was that WHO should play a role in creating knowledge-
related global public goods.
Discussion
Principal findings from the multi-method study
By drawing on three phases of data collection and multi-
ple methods, we identified seven recommendations for
those involved in establishing or leading organizations
that support the use of research evidence in developing
health policy, particularly in LMICs: 1) collaborate with
other organizations; 2) establish strong links with policy-
makers and involve stakeholders in the work; 3) be inde-
pendent and manage conflicts of interest among those
involved in the work; 4) build capacity among those
working in the organization; 5) use good methods and be
transparent in the work; 6) start small, have a clear audi-
ence and scope, and address important questions; and 7)
be attentive to implementation considerations even if
implementation is not a remit. We also identified four rec-
ommendations for WHO and other international organi-
zations and networks: 1) support collaborations among
organizations; 2) support local adaptation efforts; 3)
mobilize support; and 4) create global public goods. We
provide additional details about both methods and find-
ings in the following three articles in this series [20-22].
Strengths and weaknesses of the multi-method study
The multi-method study has six main strengths: 1) we
examined the views and experiences of those familiar with
three types of organizations that support evidence-
informed policymaking, not just one of the two types of
organizations previously studied (i.e., we surveyed GSUs
as well as CPG- and HTA-producing organizations, we
interviewed roughly equal numbers of CPG- and HTA-
producing organizations and GSUs, and the majority of
case descriptions were GSUs); 2) we achieved both
breadth (through a survey) and depth (through interviews
with directors and then case descriptions that drew both
on interviews with a range of staff, advocates and critics
and on documentary analyses) in our examination of
their views and experiences; 3) we drew on a regionally
diverse project reference group to ensure that our draft
protocol, study population, questionnaire, interview
guide, and case description data collection protocol were
fit for purpose; 4) we adapted a widely used questionnaire
and achieved a high response rate with our survey (86%);
5) we used explicit sampling criteria to identify particu-
larly successful or innovative groups for more in-depth
study through interviews and case descriptions, no organ-
ization declined to participate in the interviews, and only
one individual declined to participate in the interviews
conducted as part of the site visits; and 6) we employed a
variety of independent checks on the credibility of our
thematic analyses of the written questionnaire responses
and the interview and case descriptions data. The study
has two main weaknesses: 1) despite significant efforts to
identify organizations in LMICs, just over half (54%) of
the organizations we surveyed, and just under half (48%)
of the organizations we interviewed, were drawn from
high-income countries; and 2) despite efforts to ask ques-
tions in neutral ways, many organizations may have been
motivated by a desire to tell us what they thought we
wanted to hear (i.e., there may be a social desirability bias
in their responses).
What the multi-method study adds
This synthesis of findings from the first multi-method
study of its kind, along with the more detailed findings
from each of the three phases of the study [20-22], pro-
vides a strong basis on which researchers, policymakers
and international organizations and networks can
respond to the growing chorus of voices calling for efforts
to support the use of research evidence in developing
health policy, particularly in LMICs but also more gener-
ally. The recommendations are firmly rooted in the expe-
riences of a remarkably diverse array of organizations,
many of which are in some way successful or innovativeImplementation Science 2008, 3:53 http://www.implementationscience.com/content/3/1/53
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in supporting the use of research evidence in the develop-
ment of CPGs, HTAs, and health policy.
Implications for policymakers and for international 
organizations and networks
Policymakers can play a strong supporting role for these
organizations, both by building strong links with the
organizations while respecting their independence and by
encouraging them to follow the recommendations that
emerged from the study, such as to collaborate with other
organizations, manage conflicts of interest, build capacity,
and use good methods and be transparent in the work.
International organizations and networks also have a key
role to play in supporting collaborations among organiza-
tions, supporting local adaptation efforts, mobilizing sup-
port, and creating global public goods. Such activities
could be undertaken through international research
projects and capacity-building initiatives focused on those
organizations with significant but as yet unrealized poten-
tial and through educational and networking workshops
that bring together researchers, policymakers, and stake-
holders linked to organizations at various stages in their
development (and ideally from several different coun-
tries).
Implications for future research
A similar assessment should be repeated in a few years, by
which time many new and promising organizational
forms for supporting the use of research evidence in the
development of health policy, such as the WHO-spon-
sored Evidence-Informed Policy Networks, will have been
established [23]. These new organizational forms should
also be evaluated prospectively to identify what works
well in what contexts and why. Moreover, additional
research is needed to develop and evaluate tools that these
organizations can use to support the use of research evi-
dence in developing health policy, as is being planned by
the European Union-funded project, entitled Supporting
the Use of Research Evidence (SURE) in African Health
Systems.
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